Daiichi Sankyo and Merck report phase 2 trial results for lung cancer drug
W P Carey Inc stock reached a 52-week high, touching 67.44 USD, indicating a strong performance over the past year. With an impressive year-to-date return of 26.07%, the company has demonstrated remarkable momentum. InvestingPro analysis shows the stock is currently trading near its Fair Value, with 7 additional key insights available to subscribers. This milestone reflects a 16.92% increase in the stock’s value over the last 12 months. The company’s robust growth trajectory, marked by an impressive 92.88% gross profit margin and a generous 5.39% dividend yield, has been driven by its strategic investments and a favorable market environment. As W P Carey, with its substantial $14.74B market capitalization, continues to expand its portfolio and optimize its operations, the stock’s upward momentum and 28-year track record of consistent dividend payments highlight the company’s resilience and potential for sustained growth. Access the complete financial health analysis and detailed metrics through InvestingPro’s comprehensive research report.
In other recent news, W. P. Carey Inc. announced its second-quarter 2025 earnings, reporting an earnings per share (EPS) of $0.23, which fell short of the anticipated $0.63, resulting in a 63.49% negative surprise. Despite this, the company surpassed revenue expectations, achieving $430.78 million compared to the forecasted $401.17 million, marking a 7.38% positive surprise. Additionally, W. P. Carey completed further investments totaling $250.8 million since its second-quarter earnings release, increasing its year-to-date investment volume to approximately $1.3 billion. These investments predominantly include single-tenant industrial properties in North America and Europe. These developments highlight the company’s ongoing strategic investments and revenue growth, despite the recent earnings shortfall.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.